Clinical Trial Update: Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating MK-8353 in combination with selumetinib in advanced/metastatic solid tumors has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MK-8353
• Selumetinib (selumetinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2023-01-25